Takeda, CSL to end alliance as plasma-based COVID-19 drug fails key test

An experimental, concentrated antibody solution from Takeda and CSL Behring failed to reduce the risk of disease progression in hospitalized COVID-19 patients in a large study funded by the U.S. government.